Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

OX40-OX40L interactions: a promising therapeutic target for allergic diseases?
Yui-Hsi Wang, Yong-Jun Liu
Yui-Hsi Wang, Yong-Jun Liu
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):3655-3657. https://doi.org/10.1172/JCI34182.
View: Text | PDF
Commentary Article has an altmetric score of 3

OX40-OX40L interactions: a promising therapeutic target for allergic diseases?

  • Text
  • PDF
Abstract

Recent advances in understanding the cellular and molecular mechanisms of atopy have shed light on potential targets for the development of new therapies for allergic diseases. In this issue of the JCI, Seshasayee et al. provide direct in vivo evidence that OX40 has critical roles in allergic inflammation mediated by thymic stromal lymphopoietin (TSLP) (see the related article beginning on page 3868). Blockade of interactions between OX40 on Th2 cells and OX40 ligand (OX40L) on TSLP-activated DCs using an OX40L-specific monoclonal antibody, inhibited Th2 cell–mediated immune responses in both mouse and nonhuman primate models of allergic inflammation. The results point to potential therapeutic approaches to targeting the cellular and molecular mechanism underlying TSLP-mediated allergic inflammation.

Authors

Yui-Hsi Wang, Yong-Jun Liu

×

Total citations by year

Year: 2024 2023 2022 2021 2019 2017 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 1 1 1 1 1 3 3 1 1 1 3 1 1 1 20
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (20)

Title and authors Publication Year
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Waligóra-Dziwak K, Dańczak-Pazdrowska A, Jenerowicz D
Journal of Clinical Medicine 2024
Berry Extracts and Their Bioactive Compounds Mitigate LPS and DNFB-Mediated Dendritic Cell Activation and Induction of Antigen Specific T-Cell Effector Responses
Upadhaya P, Lamenza FF, Shrestha S, Roth P, Jagadeesha S, Pracha H, Horn NA, Oghumu S
Antioxidants 2023
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
Lé AM, Torres T
Pharmaceutics 2022
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis
N Yang, Z Chen, X Zhang, Y Shi
BioDrugs 2021
Statins can suppress DC‐mediated Th2 responses through the repression of OX40‐ligand and CCL17 expression
N InagakiKatashiba, T Ito, M Inaba, Y Azuma, A Tanaka, V Phan, K Kibata, A Satake, S Nomura
European Journal of Immunology 2019
Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System
I Mizoguchi, M Ohashi, Y Chiba, H Hasegawa, M Xu, T Owaki, T Yoshimoto
Frontiers in immunology 2017
Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
X Wang, X Jiang, X Yu, H Liu, Y Tao, G Jiang, M Hong
Journal of Cellular and Molecular Medicine 2017
Yi-Qi-Ping-Chuan-Fang Reduces TSLP Elevation Caused by LPS + Poly(I:C) via Inhibiting TLR4/MYD88/NF- κ B Signaling Pathway
M Qu, X Tao, J Ma
Evidence-Based Complementary and Alternative Medicine 2017
Anti-OX40L alone or in combination with anti-CD40L and CTLA4Ig does not inhibit the humoral and cellular response to a major grass pollen allergen
M Gattringer, U Baranyi, N Pilat, K Hock, C Klaus, HE Ramsey, F Wrba, R Valenta, T Wekerle
Clinical & Experimental Allergy 2016
Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis
X Zheng, J Yao, B Li
Journal of Ophthalmology 2016
Dectin-1 in the control of Th2-type T cell responses
Upchurch K, Oh S, Joo H
Receptors & Clinical Investigation 2016
Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma
J Lee, TH Kim, F Murray, X Li, SS Choi, DH Broide, M Corr, J Lee, NJ Webster, PA Insel, E Raz
Proceedings of the National Academy of Sciences 2015
Screening active components from yu-ping-feng-san for regulating initiative key factors in allergic sensitization
D Shen, X Xie, Z Zhu, X Yu, H Liu, H Wang, H Fan, D Wang, G Jiang, M Hong
PloS one 2014
Effect of Rosuvastatin on OX40L and PPAR-γ Expression in Human Umbilical Vein Endothelial Cells and Atherosclerotic Cerebral Infarction Patients
JY Zhang, B Liu, YN Wang, WN Zhang, FJ Wang
Journal of Molecular Neuroscience 2013
Novel Identified Receptors on Mast Cells
H Migalovich-Sheikhet, S Friedman, D Mankuta, F Levi-Schaffer
Frontiers in immunology 2012
Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand
J Han, A Dakhama, Y Jia, M Wang, W Zeng, K Takeda, Y Shiraishi, M Okamoto, SF Ziegler, EW Gelfand
Journal of Allergy and Clinical Immunology 2012
Mast Cell-Airway Smooth Muscle Crosstalk
D Kaur, C Doe, L Woodman, WY Wan, A Sutcliffe, F Hollins, C Brightling
Chest 2012
Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus
X Zhou, X Lu, SK Nath, J Lv, S Zhu, H Yang, L Qin, M Zhao, Y Su, N Shen, Z Li, H Zhang
Arthritis & Rheumatism 2011
TSLP and downstream molecules in experimental mouse allergic conjunctivitis
X Zheng, P Ma, CS de Paiva, MA Cunningham, CS Hwang, SC Pflugfelder, DQ Li
Investigative ophthalmology & visual science 2010
Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses
YH Wang, YJ Liu
Cell 2009

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
39 readers on Mendeley
See more details